Pemetrexed patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11147817 SHILPA Pharmaceutical composition of pemetrexed
Mar, 2035

(11 years from now)

Pemetrexed is owned by Shilpa.

Pemetrexed contains Pemetrexed Disodium.

Pemetrexed has a total of 1 drug patent out of which 0 drug patents have expired.

Pemetrexed was authorised for market use on 22 May, 2023.

Pemetrexed is available in solution;intravenous dosage forms.

The generics of Pemetrexed are possible to be released after 26 March, 2035.

Drugs and Companies using PEMETREXED DISODIUM ingredient

Market Authorisation Date: 22 May, 2023

Treatment: NA


More Information on Dosage

PEMETREXED family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic